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Abstract
Background: Circulating free light chains (FLCs) can alter neutrophil migration, apoptosis and activation and may
be a biomarker of autoimmune disease and adaptive immune system activation. These pathogenic roles could be
relevant to lung disease in alpha 1 antitrypsin deficiency (A1ATD) and chronic obstructive pulmonary disease
(COPD).
Methods: Total combined (c)FLCs were measured using the FreeLite® assay in 547 patients with A1ATD and 327
patients with usual COPD in the stable state, and assessed for association with clinical phenotype, disease severity,
airway bacterial colonisation and mortality. Univariate and multivariate analyses were undertaken.
Results: Circulating cFLCs were static in the stable state when measured on 4 occasions in A1ATD and twice in
usual COPD. Levels were inversely related to renal function (A1ATD and COPD p = <0.01), and higher in patients
with chronic bronchitis (p = 0.019) and airway bacterial colonisation (p = 0.008). After adjusting for renal function
and age the relationship between cFLCs and lung function was weak. Kaplan Meier curves showed that cFLC >
normal (43.3 mg/L) significantly associated with mortality in both cohorts (A1ATD p = 0.001, COPD p = 0.013).
Conclusions: cFLCs may be a promising biomarker for risk stratification in A1ATD and COPD.
Keywords: Chronic obstructive pulmonary disease, Emphysema, Alpha 1 antitrypsin deficiency, Mortality,
Exacerbations, Immunoglobulin light chains
At a glance commentary
Scientific knowledge on the subject
Circulating free light chains are a potential biomarker
of adaptive immune activation, which influence neu-
trophil function and are elevated in an animal model
of emphysema. The ADAPT and WMCC cohorts re-
ceived ethical approval from the South Birmingham
National Research Ethics Service (NRES) committee
(ADAPT ethics approval number 3359a, WMCC REC
ref no. 07/H1207/231). The IRF Usual COPD cohort
received ethical approval from the East Midlands
NRES committee (REC ref no.12/EM/0090).
What this study adds to the field
Circulating free light chains relate to clinical phenotype and
prognosis in both A1ATD and usual COPD, and are ele-
vated in the context of a possible stimulus to the adaptive
immune system, namely chronic bacterial colonization of
the airway.
Background
Chronic obstructive pulmonary disease (COPD) is an in-
flammatory lung disease characterised by persistent air-
flow obstruction, which usually progresses [1]. Immune
activation may be one of the factors perpetuating inflam-
mation in COPD [2]. The immune response seen in
COPD incorporates cells from innate and adaptive im-
mune systems [3]; an essential component of adaptive im-
munity is the production of antibodies by mature B
lymphocytes. Antibodies are immunoglobulins which are
composed of two polypeptide heavy chains and two light
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chains. During antibody production there is an excess of
free light chains (FLCs) produced which are secreted into
the circulation before undergoing renal clearance [4].
There are two free light chain isotypes: kappa (κ) and
lambda (λ), which can be measured by a highly sensitive
assay [5]. High FLC levels occur in several autoimmune
and inflammatory conditions, thus suggesting they may be
a biomarker of adaptive immune activation [4]. Raised
polyclonal FLCs have also been reported in a number of
respiratory conditions where adaptive immunity may be
important, including asthma [6] and COPD [7].
In addition to being a marker of immune activation,
FLCs could have a direct pathogenic role in COPD. They
inhibit neutrophil apoptosis [8], inhibit neutrophil mi-
gration in vitro [9], and are elevated in both murine
models of emphysema and serum from patients with
COPD [7]. In addition FLCs bind to human neutrophils,
activating them to produce IL8 in vitro; specific FLC an-
tagonism inhibited this binding capability and reduced
pulmonary neutrophilia in smoke exposed mice [7].
The primary aim of this study was to investigate the
clinical utility of FLCs as a biomarker in patients with
alpha-1-antitrypsin deficiency (A1ATD). We hypothesised
that FLCs would be static in stable disease, relate to dis-
ease severity, distinguish clinically relevant subgroups, re-
late to factors which could stimulate the adaptive immune
system and associate with longitudinal outcomes, such as
mortality. We then sought to replicate these associations
in “usual” (non A1ATD) COPD. Furthermore we hypothe-
sised that levels would be similar in usual COPD to
A1ATD, since pulmonary immune activation has recently
been shown to be similar between these groups [10].
Methods
Study design and population
Patients with severe A1ATD (defined as a level of <11 μM
and phenotype PiZZ, PiZnull or other dysfunctional vari-
ants) were selected from the UK A1ATD registry (n = 547).
Recruitment and follow up procedures are described in de-
tail elsewhere [11]; briefly patients attend annually for re-
view, and are followed up until death. Lung function has
been calculated on all patients with at least 3 years of serial
lung function [12]. The usual COPD cohort (n = 327) com-
prised all patients in the West Midlands COPD Collection
(WMCC), recruitment procedures for which are described
elsewhere [13], and a second cohort recruited through the
Inflammation Research Facility (IRF) at Queen Elizabeth
Hospital. The IRF cohort has superceded the WMCC and
largely replicates assessment procedures of the UK A1ATD
registry, again following up annually until death. Both co-
horts were reviewed in the stable state only, thus were only
suitable for repeated measurement of cFLC levels in stable
disease, cross-sectional analyses of clinical phenotype (in-
cluding relevant co-morbidities) and survival analysis. All
studies were approved by the local ethics committee and
patients gave informed consent.
Baseline demographic data including age, sex and pack
years smoked was collated for all cohorts. CT scans were
examined for evidence of emphysema and bronchiectasis
and post-bronchodilator lung function recorded. Symp-
tom history (e.g., presence of chronic bronchitis), annual
exacerbation frequency and mortality were noted. The ex-
acerbation history was assessed using the criteria sug-
gested by Anthonisen et al. of increased breathlessness,
sputum volume and sputum purulence [14]. In addition,
we recorded patients’ renal function as measured by their
creatinine and urea, and calculated the estimated glom-
erular filtration rate (eGFR) [15]. In the A1ATD cohort,
stable state quantitative sputum culture results were ex-
amined to establish if patients were chronically colonised
with pathogens (≥1x105 cfu/ml in ≥3 samples over
≥3 months [16]). Although patients with stable COPD
were asked to provide sputum samples, identical to the
A1ATD group, there were too few for meaningful analysis.
FLC analysis
The FLC analysis was performed on serum or plasma in
all patients using the Freelite® immunoassay (Binding site
Group Ltd, Birmingham, UK), summating κ and λ values
to give a combined (c)FLC result, as it is the combined
level which has been of relevance in past studies of other
diseases and in the general population. Reference ranges
were combined (κ&λ) FLC (cFLC) 9.3–43.3 mg/L [17]
and κ/λ ratio 0.26–1.65 [18]. Patients with an abnormal
κ/λ ratio (suggestive of possible underlying monoclonal
gammopathy) were excluded from analysis. We con-
ducted experiments using matched serum and plasma
samples demonstrating equivalence of measures in the
two sample types (Additional file 1). In 19 A1ATD pa-
tients and 59 usual COPD patients with stable disease
(according to both history and serial lung function) we
performed FLC analysis on ≥2 samples collected over a
period ranging from 1 to 4 years to assess whether levels
were static in stable patients.
Statistical analysis
All analyses were performed using IBM SPSS statistics
version 20. Data distribution was assessed and univariate
analyses performed using Mann Whitney U tests or
Spearmen’s Rho (rs) correlations; results are presented as
median (IQR). Relationships between cFLC and all vari-
ables shown in Table 1 were examined in A1ATD and
usual COPD, as were current smoke exposure and air-
way bacterial colonisation (potential immune activation
triggers). Multivariate analytic techniques were then
used to adjust for covariates where needed; renal func-
tion (eGFR) was included in all regression analyses.
A1ATD and COPD were subsequently compared using
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logistic regression, including as covariates eGFR and
those factors relating to cFLC levels that differed be-
tween the 2 cohorts. The Friedman test was used to es-
tablish whether cFLC measures were static in stable
patients. For the mortality analyses survival time was de-
fined as time from date of sample collection to analysis
date; univariate and multivariate Cox regression analyses
were performed, selecting regression covariates if p < 0.1
in the univariate analysis, and no significant collinearity
with other variables. Cox regression was conducted
using cFLC as a continuous variable and also using 2 im-
portant threshold levels – the upper limit of normal
(43.3 mg/L) and the threshold associated with death
within 100 days (65 mg/L [19]). Kaplan – Meier curves
were drawn to compare these thresholds.
Results
Stable A1ATD
Median follow up time was 5.7 (3.9–7.7) years. The demo-
graphics of the cohort are outlined in Table 1. Eighty four
percent of patients had post-bronchodilator airflow obstruc-
tion (defined as an FEV1/FVC ratio <0.7); 8 of those without
obstruction had emphysema on CT scan. Seven patients
were excluded due to an abnormal κ/λ ratio. At least one
autoimmune disease was present in 15.6 % of patients (n =
84), the most common being thyroid disease (4.1 %, n= 22),
diabetes (3.1 %, n= 17), ulcerative colitis (2.1 %, n= 11),
psoriasis (1.3 %, n = 7) and vasculitis (0.9 %, n = 5). cFLC
levels did not differ between patients with and without auto-
immune disease (p= 0.125) and there was no difference in
the number of autoimmune conditions exhibited by patients
with cFLC levels outside the normal range (>43.3 mg/L; p=
0.320) compared to those with normal levels. There was no
significant difference in cFLCs taken at 4 time points in
stable disease (p= 0.116).
Cross sectional univariate analyses of COPD phenotype and
clinical features against cFLC
There was a weak negative correlation between cFLC level
and eGFR (rs =−0.14, p = 0.003), consistent with the differ-
ence seen between CKD stage groups (p = 0.006; Fig. 1).
Age also correlated with cFLCs (rs = 0.15, p = 0.001), but
this relationship disappeared after adjustment for eGFR
rs = 0.08, p = 0.101), suggesting this was primarily due
to worsening renal function with age. Given the renal
clearance of FLCs the relationship to eGFR was ex-
pected but important to confirm.
Table 1 Characteristics of the A1ATD and usual COPD cohorts
Variable A1ATD cohort (n = 540) Usual COPD cohort (n = 316) p
Age 53.9 (45.0–60.9) 68.8 (61.5–75.1) <0.001
Sex Male n = 311 (57.6 %) Male n = 182 (57.6 %) 0.999
Female n = 229 (42.4 %) Female n = 134 (42.4 %)
Pack years 11.6 (0.0–24.0) 44.1 (29.5–62.2) <0.001
FEV1 (% predicted) 50.7 (35.1–85.1) 46.4 (35.0–61.0) <0.001
KCO (% predicted) 62.3 (49.3–77.0) 59 (47.5–77.0) 0.533
Chronic bronchitis 185 (34.3 %) 198 (62.7 %) <0.001
Emphysema 358 (66.3 %) 257 (81.3 %) 0.002
Bronchiectasis 142 (26.3 %) 96 (30.3 %) 0.678
Frequent exacerbator 129 (40.8 %) 193 (61.1 %) <0.001
eGFR 81.3 (70.6–93.9) 85.8 (69.7–101.1) 0.063
CKD stage 0.002
1 eGFR≥ 90 156 (28.9 %) 119 (37.6 %)
2 eGFR 60–89 279 (51.7 %) 130 (41.1 %)
3 eGFR 30–59 41 (7.6 %) 35 (11.1 %)
4 eGFR 15–29 2 (0.4 %) 4 (1.3 %)
5 eGFR < 15 1 (0.2 %) 0 (0 %)
Unknown (no eGFR) 61 (11.3 %) 28 (8.9 %)
cFLC (mg/L) 25.7 (21.1–31.7) 31.9 (24.0–43.3) <0.001
κ/λ 0.86 (0.71–1.08) 0.86 (0.72–1.06) 0.967
Number of patients with contemporaneous renal function = 479 A1ATD, 288 usual COPD. Continuous variables expressed as median (IQR); sex, chronic bronchitis,
emphysema, bronchiectasis, exacerbators and CKD stage expressed as number in each group (%). A frequent exacerbator was defined as having 2 or more
exacerbations per year. BMI body mass index, FEV1 forced expiratory volume in 1 s, KCO corrected gas transfer, eGFR estimated glomerular filtration rate, cFLC
combined (κ + λ) free light chain level (mg/L)
P values highlighted in bold indicate significant differences between the A1ATD and Usual COPD cohorts (p ≤ 0.05)
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Analyses controlling for eGFR and age demonstrated
weak correlations between cFLC and lung function
(FEV1 r = 0.13, p = 0.012, KCO r = 0.10, p = 0.046). No
significant differences were seen with respect to presence
of bronchiectasis or emphysema, or frequent exacerba-
tions (defined as ≥2 per year). Patients with chronic bron-
chitis had significantly higher cFLCs compared to those
without (27.0 (21.1–33.6) v 25.0 (20.8–30.8); p = 0.019).
No significant relationships were seen between cFLC
and smoke exposure (either current smoking status or
pack years). Sputum specimens during stable disease
were available in 152 patients. Of these, 53 had no posi-
tive sputum cultures and 12 were chronically colonised
with ≥1 potentially pathogenic organism. Patients who
were chronically colonised had significantly higher
cFLCs compared to patients with no positive cultures
(Fig. 2; 35.7 (26.4–42.4) v 26.3 (22.0–31.2) p = 0.008).
Longitudinal outcomes and cFLC levels
Sixty nine (12.8 %) patients died. Patients who died had
significantly higher baseline cFLCs compared to those
who remained alive (29.2 (22.7–39.9) v 25.2 (21.0–
31.0), p = 0.001). Multivariate analysis by Cox regression,
to assess whether cFLC associated with mortality, showed
that cFLC, increasing age and lower FEV1 (all p < 0.001)
significantly predicted death, with a cFLC level above the
normal range conferring an odds ratio for death of 2.89
(1.47–5.70) p = 0.002. The Kaplan-Meier plots showed sig-
nificant differences in the survival curves according to
both this level and the higher figure of 65 mg/L (Fig. 3).
However cFLCs were not a sufficiently sensitive or specific
test to perform well in ROC curves plotted against mortal-
ity (AUC for either threshold <0.62).
Stable usual COPD
The median follow up time was 2.5 (1.5–4.7) years. Clin-
ical features and demographics are shown in Table 1.
Eleven patients were excluded due to an abnormal κ/λ
ratio.
As in A1ATD levels remained static in stable disease
(p = 0.153). There was a similar relationship between
cFLC level, eGFR and CKD stages to that observed in
A1ATD (Fig. 1), although the degree of variability in
usual COPD was greater than A1ATD, perhaps due to
higher clinical heterogeneity of usual COPD compared
to A1ATD. The correlation between cFLC and eGFR
was also reduced by adjustment for age, but did not dis-
appear. Unlike A1ATD, men had significantly higher
cFLC levels than women (35.4 (27.4–47.2) v 29.51
(21.6–38.8), p < 0.001). Similar regression analyses to
A1ATD were performed, with the addition of sex as a
covariate. Higher cFLC levels also tended to occur with
A1ATD
b
c d
Usual COPD
a
Fig. 1 Stable state cFLC levels relate to renal function. Scatter plots (a, b) and bar charts (c, d) showing the relationship between cFLC (mg/L),
eGFR (ml/min/1.73 m2) and chronic kidney disease (CKD) stage in the stable state in A1ATD and usual COPD patients respectively. P values are for
2 tailed univariate statistics. A1ATD (a) rs = −0.14, p = 0.003 (c) p = 0.006. Usual COPD (b) rs = −0.24, p = <0.001 (d) p = <0.001. A1ATD CKD stage 1
(n = 156), 2 (n = 279), 3 (n = 41), 4 (n = 2), 5 (n = 1). Usual COPD CKD stage 1 (n = 119), 2 (n = 130), 3 (n = 35), 4 (n = 4), 5 (n = 0)
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chronic bronchitis (34.1 v 32.3; p = 0.087) and the lack of
relationship to bronchiectasis and emphysema persisted.
Longitudinal outcomes and cFLC levels
Ninety one (28.8 %) patients died. The relationship be-
tween higher cFLCs and subsequent death was repli-
cated in usual COPD (36.4 (26.0–51.5) v31.5 (23.3–
41.3), p = 0.014), and the multivariate model confirmed
that cFLC remained independently associated with mor-
tality, with a level above the normal range conferring an
odds ratio of 1.80 (1.16–2.80), p = 0.009. Similar patterns
were seen in the Kaplan-Meier curves (Fig. 3).
Comparison of A1ATD and usual COPD
The primary purpose of this analysis was to compare the
cFLC levels between the 2 groups, rather than their clin-
ical features, as cohorts were recruited in different set-
tings, and differences between A1ATD and usual COPD
are well known. Since cFLC related to several clinical
features in both A1ATD and usual COPD it was neces-
sary to adjust by regression analysis for these features
prior to comparing cFLC levels; this was particularly im-
portant because most of these also differed between
A1ATD and our usual COPD cohort (Table 1). This was
achieved by forced entry of eGFR, FEV1 % predicted,
presence of chronic bronchitis and age as covariates in a
linear regression seeking associations of cFLC levels, to
which the presence of A1ATD was then added as a final
variable. Since cFLC were non-normally distributed the
values were logged prior to regression analysis, which
then resulted in normal distribution of the subsequent
standard residuals.
Combined free light chain levels appeared higher in
usual COPD than A1ATD (Table 1). A1ATD was a sig-
nificant predictor of lower cFLCs independent of eGFR,
FEV1, chronic bronchitis and age (p < 0.001; Table 2).
Discussion
Our main objective was to investigate the utility of
measuring polyclonal FLCs as a clinical biomarker in se-
vere A1ATD and usual COPD. Key properties of a clin-
ically useful biomarker are that it is reproducible in
stable disease, relates to disease severity and relates to
outcome. Our results demonstrate that cFLCs meet
many of these criteria, notably being associated with
subsequent mortality in both our cohorts. No significant
difference was seen in cFLCs taken from patients with
stable disease at different time points, suggesting that
cFLCs are reproducible in stable disease. We did not see
a strong relationship between cFLC levels and disease
severity, although there was a difference observed be-
tween patients with and without chronic bronchitis,
which is recognised to be a clinically relevant subgroup
within airways disease [20].
A role for the adaptive immune system in perpetuation
of inflammation in COPD has been proposed, since ac-
cumulation of B cells in large and small airways associ-
ates with worsening disease severity [21]. FLCs,
produced as a by-product of immunoglobulin synthesis
by mature B cells, could be a useful marker of adaptive
Fig. 2 Relationship of cFLC levels to airway bacterial colonisation. The graph shows a univariate comparison between colonised and non-colonised
individuals with A1ATD, each dot represents a patient, and the horizontal line is the median per group, p = 0.008. (cFLC = combined κ & λ mg/L)
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immune system activity [4]. The prevalence of other
autoimmune diseases was low in our A1ATD cohort,
and no relationships were seen between cFLC levels and
autoimmune disease burden. However, prior studies sug-
gest that cFLCs change during periods of disease ‘activ-
ity’ (e.g. in rheumatoid arthritis [22] and systemic lupus
erythmatosus [23]) such that presence of well controlled
(inactive) autoimmune conditions might explain the lack
of association observed. Furthermore, many important
questions regarding the role B cells play in the develop-
ment of COPD remain unanswered. For example, which
antigens drive the B cell response? Is the response
a b
c d
A1ATD
Fig. 3 Kaplan-Meier curves exploring the cut-off level of cFLC which relates to death. Kaplan-Meier survival curves according to cFLC levels in the
A1ATD and usual COPD cohorts, solid lines representing those with levels below the specified threshold and dotted lines those with a level above
it. A1ATD cohort ≥43.3 mg/L (n = 33), <43.3 mg/L (n = 507), ≥65 mg/L (n = 7), <65 mg/L (n= 533). Usual COPD cohort ≥43.3 mg/L (n = 79), <43.3 mg/L
(n = 237), ≥65 mg/L (n = 24), <65 mg/L (n= 292). Please note the differing time scales, due to longer duration of follow up in A1ATD. All statistics are
by log-rank test, and plots are unadjusted for covariates. A1ATD a Threshold of normal range (43.3 mg/L) p = 0.001 c Threshold ≥65 mg/L p <0.001.
Usual COPD b Threshold of normal range p = 0.013 d Threshold ≥65 mg/L p = 0.012
Table 2 Linear regression analysing log cFLC in all stable patients
Variable B (95 % CI) R2 change F change P (F change)
eGFR −0.001 (−0.002–−0.001) 0.04 19.94 <0.001
Age 0.001 (0–0.003) 0.03 16.40 <0.001
Chronic bronchitis 0.033 (0.007–0.06) 0.02 9.72 0.002
FEV1% predicted 4.8 × 10−4 (0–0.001) 0.01 3.00 0.084
A1ATD −0.09 (−0.133–−0.053) 0.03 21.10 <0.001
The table shows the regression coefficients (B) and significance of variables. The two most important variables in the model were eGFR and A1ATD
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specific to the lung or not? If it were lung specific,
then this might account for the lack of relationship to
co-morbid systemic diseases linked to immune activa-
tion. Commonly hypothesised antigen sources are
microbes colonising the airways, smoke constituents
and breakdown products of the extracellular matrix
[24]. In the A1ATD cohort we found that chronically
colonised patients had significantly higher cFLC
levels, supporting the hypothesis that colonisation
may be an important driving force behind adaptive
immune activation.
Another theory is that infection or colonisation with
bacteria leads to a breakdown in self – tolerance pro-
moting an immune reacton to self-antigens. This con-
cept is well established in a number of autoimmune
diseases [25] and there is some evidence supporting an
autoimmune element to COPD [2]. The difference in
cFLC observed between usual COPD and A1ATD imply
that this is a more important pathogenic theme in usual
COPD, although this does not exclude immune activa-
tion contributing to the disease process in A1ATD. This
result is contrary to the recent report of equivalent levels
of lymphoid follicles in lung tissue from a small cohort
of A1ATD patients with very severe lung disease, com-
pared to usual COPD [10]. It is possible that immune
activation represents a feature of advanced disease in
both conditions, as most of our patients had severe dis-
ease, thus further studies are indicated.
Mechanistically cFLCs have biological properties that
could potentially damage lung tissue through interaction
with neutrophils [7–9]. We have shown previously that
migratory accuracy of neutrophils is lower in COPD
than A1ATD [26]; it is possible that cFLCs might be
partly responsible since cFLCs were significantly higher
in COPD in our study. Furthermore several case reports
detail nodular and cystic lung disease associated with
cFLC overproduction in light chain deposition disease
(LCDD) [27–30], which is characterised by the depos-
ition of non-amyloid κ or λ light chains, and presents
with progressive cystic lung disease ultimately leading to
respiratory failure necessitating lung transplantation
[29]. It is possible to therapeutically antagonise cFLCs
using the compound F991 in animals [6, 7, 31]. Thus it
remains important to clarify whether the pro-
inflammatory effects of cFLCs play a role in COPD, and
thus represent a suitable drug target.
Our results also demonstrated that patients with
chronic bronchitis had significantly higher cFLCs,
suggestive of a greater adaptive immune response in
these individuals. Chronic bronchitis is associated
with more rapid FEV1 decline [32], increased exacer-
bation frequency [33] and a greater risk of mortality
[34]. However, the difference between cFLCs in pa-
tients with chronic bronchitis compared to those
without was relatively small, thus the result must be
interpreted with caution in terms of clinical signifi-
cance. The sex difference in cFLCs in usual COPD
was unexpected. There is known to be a male pre-
dominance in haematological conditions associated
with monoclonal overproduction of FLCs such as
monoclonal gammopathy of unknown significance
(MGUS) and multiple myeloma [35] however in our
study, any patients with an abnormal κ/λ were
exluded from the analysis, hence undetected gammo-
pathies would not have influenced our results.
Finally, we have shown that raised circulating cFLC
levels are a predictor of mortality, independent of age
and severity of renal impairment. Several studies have
shown a link between immune system activity, inflam-
mation and risk of death: an increase in polyclonal
cFLCs predicted mortality in the general population [17]
and cFLC >65 mg/L were a risk factor for death within
100 days [19]. The association between inflammation
and cardiovascular death is well reported [36], and 41 %
of the deaths in those with cFLC > 65 mg/L were from
cardiovascular disease [17]. A recent systematic review
supported the concept that the relationship between car-
diovascular disease and COPD goes beyond common
aetiological factors such as smoking [37]; cFLCs could
partly explain this.
Our study is limited by the relative lack of colonisation
data in A1ATD and absence of this information in usual
COPD. Our A1ATD cohort is similar in disease severity
to the American A1ATD registry [38], thus results are
likely to be generalisable to other A1ATD populations.
However the usual COPD group generally had severe
COPD, and exhibited high prevalence of emphysema,
thus our results may be less generalisable to milder usual
COPD cohorts. The severity of their disease is
highlighted by the significant differences relative to
A1ATD, who in many cases appear less unwell. This is
in part due to the inclusion of family screened, non-
index cases in A1ATD, but not usual COPD. It would
also be of interest to measure cFLCs in an adequate
number of exacerbations of COPD, to see if flare ups of
disease relate to cFLC levels, as they do in some auto-
immune diseases. Sample collection for this is now
ongoing.
Conclusions
To our knowledge this is the first study to evaluate the
utility of cFLCs as a clinical biomarker in A1ATD and
usual COPD. Elevated FLCs independently predict
mortality in patients with severe A1ATD and usual
COPD and could play a role in risk-stratification of
patients requiring more intensive monitoring and
management.
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